The Lancet

Pfizer Inc (NYSE: PFE) and its partner BioNTech SE’s (NASDAQ: BNTX) COVID-19 vaccine’s effectiveness against the disease wanes with time but its protection against hospitalization remains, as per a study. What Happened: The vaccine’s effectiveness declined from a peak of 88% a...

A new Hong Kong study has found that people fully vaccinated with the BioNTech SE (NASDAQ: BNTX) COVID-19 shot have ten times higher antibody concentrations than those who have received inactivated vaccines like China’s Sinovac Biotech Ltd (NASDAQ: SVA), ...

Bristol Myers Squibb Co (NYSE: BMY) announced a new analysis of data from the Phase 3 EXPLORER-HCM study evaluating mavacamten in patients with obstructive hypertrophic cardiomyopathy (oHCM). New data were presented at the American College of Cardiology Annual Scientific...

VBI Vaccines Inc (NASDAQ: VBIV) has announced that results from Phase 3 PROTECT trial of VBI's prophylactic 3-antigen hepatitis B (HBV) vaccine candidate in adults were published in The Lancet Infectious Diseases. The study was designed to compare the immunogenicity and...

NewLink Genetics Corp (NASDAQ: NLNK) and licensing partner Merck & Co., Inc. (NYSE: MRK) appear to have made a major breakthrough in prevention of one of the deadliest diseases in the world. This week, The Lancet reported 100 percent efficacy in Merck's final-stage trial of an experimental...